Tatva Chintan Pharma Chem Ltd

Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 31 March 2023 in the prescribed format. The same will be filed in XBRL mode separately.We confirm that as at 31 March 2023 there has not been any deviation(s) or variation(s) in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated 22 July 2021.Report issued by Monitoring agency report is being separately filed with the exchange.The above information shall be made available on the website of the Company at www.tatvachintan.com.